The South African National Department of Health is expected to roll out a clinical access programme to allow drug-resistant tuberculosis (DR-TB) patients access to the new drug delamanid.

In just four years, South Africa has seen a 40-fold increase in health facilities treating drug-resistant tuberculosis (DR-TB) as government pledges more than R130 million for new medicines.

HIV and tuberculosis (TB) drug stock outs have hit about 14 percent of health facilities nationwide in the last nine months, according to a new study released today by civil society coalition the Stop Stock Outs Project.

Health Minister Dr Aaron Motsoaledi has blamed manufacturers for shortages of medicines including HIV and tuberculosis drugs, but a civil society coalition has alleged 80 percent of stock outs are due to poor management.

South African scientists are spearheading the world’s first trial into shorter and better treatment for tuberculosis (XDR-TB), which kills about half of all those diagnosed with the condition in South Africa.

Phumeza Tisile, 24, was told that she would die three times before she beat extensively drug-resistant tuberculosis (XDR-TB). She survived but lost her hearing. Now, an outpouring of goodwill has given it back to her.

Better data has revealed more than half a million more tuberculosis (TB) cases than previously thought, according to a World Health Organisation (WHO) report released yesterday (22 October).

As extensively drug-resistant tuberculosis (XDR-TB) patients beg for a new patent policy to allow them affordable treatment, multinational pharmaceutical companies have objected to some of the draft policy’s key tenets.

With treatment priced out of reach, some extensively drug-resistant tuberculosis (XDR-TB) patients face a tough choice: Break the law or die.

South African sex workers may have one of the world’s highest HIV prevalence rates and addressing this is just one of six ways South African National AIDS Council (SANAC) CEO Dr Fareed Abdullah says the country can fix its HIV response.